Crossmark

Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients

Crossref DOI link: https://doi.org/10.1186/s40360-018-0221-6

Published Online: 2018-06-25

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Molanaei, Hadi

Qureshi, Abdul Rashid

Heimbürger, Olof

Lindholm, Bengt

Diczfalusy, Ulf

Anderstam, Björn

Bertilsson, Leif

Stenvinkel, Peter http://orcid.org/0000-0002-8785-4820
Funding

Funding for this research was provided by:

Vetenskapsrådet (K2014-65X-15320-10-3)

ALF Stockholm Council

Westman

Njurfonden
License Information

Text and Data Mining valid from 2018-06-25
More Information

Article History

Received: 17 August 2017

Accepted: 3 June 2018

First Online: 25 June 2018

Ethics approval and consent to participate

: The study was performed at the Karolinska University Hospital, Stockholm, Sweden. The Ethics Committee of Karolinska Institutet, Stockholm approved the study. All the participants in the study gave their written informed consent following verbal and written information.

: Bengt Lindholm is employed by Baxter Healthcare Corporation. None of the other authors declare any conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.